Inventor · disambiguated record
Mark J. Ratain
Also filed as: RATAIN MARK J
7 granted patents·18 pending applications·241 citations·filing 1995–2024
86Inventor score
Top patents by PatentIndex Score
25 records- 0190US6472157B2Methods for detection of promoter polymorphism in a UGT gene promoterARCH DEV CORP·Filed 2002·Granted Oct 29, 2002·40 cites·26 claims
- 0289US2024318232A1Method for Identification of Sensitivity of a Patient to Telomerase Inhibition TherapyGERON CORP·Filed 2023·Application pending·0 cites
- 0388US5786344ACamptothecin drug combinations and methods with reduced side effectsARCH DEV CORP·Filed 1995·Granted Jul 28, 1998·153 cites·30 claims
- 0485US6395481B1Methods for detection of promoter polymorphism in a UGT gene promoterARCH DEV CORP·Filed 1999·Granted May 28, 2002·42 cites·63 claims
- 0583US8877723B2Method for identification of sensitivity of a patient to telomerase inhibition therapyHARLEY CALVIN B·Filed 2009·Granted Nov 4, 2014·4 cites·17 claims
- 0682US2023114322A1Method for Identification of Sensitivity of a Patient to Telomerase Inhibition TherapyGERON CORP·Filed 2022·Application pending·0 cites
- 0780US2022325327A1Method for Identification of Sensitivity of a Patient to Telomerase Inhibition TherapyGERON CORP·Filed 2021·Application pending·0 cites
- 0878US10196677B2Method for identification of sensitivity of a patient to telomerase inhibition therapyGERON CORP·Filed 2017·Granted Feb 5, 2019·1 cites·17 claims
- 0976US9617583B2Method for identification of sensitivity of a patient to telomerase inhibition therapyGERON CORP·Filed 2014·Granted Apr 11, 2017·1 cites·10 claims
- 1075US2021269861A1Method for Identification of Sensitivity of a Patient to Telomerase Inhibition TherapyGERON CORP·Filed 2020·Application pending·0 cites
- 1171US2009318487A1Methods for detection of promoter polymorphism in a UGT gene promoterDI RIENZO ANNA·Filed 2009·Application pending·0 cites
- 1268US2025188175A1Low-dose tocilizumab for the treatment or prevention of sickle cell crisisUNIV CHICAGO·Filed 2024·Application pending·0 cites
- 1368US2019382829A1Method for Identification of Sensitivity of a Patient to Telomerase Inhibition TherapyGERON CORP·Filed 2018·Application pending·0 cites
- 1462US2007092902A1Methods for Detection of Promoter Polymorphism in UGT Gene PromoterDI RIENZO ANNA·Filed 2006·Application pending·0 cites
- 1558US2006147907A9Methods for detection of promoter polymorphism in a UGT gene promoterARCH DEV CORP·Filed 2002·Application pending·0 cites
- 1655US2009197922A1Compositions and methods for treating pulmonary hypertensionUNIV CHICAGO·Filed 2007·Application pending·0 cites
- 1754US7807350B2Methods for predicting irinotecan toxicityUNIV CHICAGO·Filed 2004·Granted Oct 5, 2010·0 cites·14 claims
- 1849US2009247475A1Methods and compositions relating to pharmacogenetics of different gene variants in the context of irinotecan-based therapiesUNIV CALIFORNIA·Filed 2006·Application pending·0 cites
- 1946US2004203034A1Optimization of cancer treatment with irinotecanUNIV CHICAGO·Filed 2004·Application pending·0 cites
- 2046US2016239636A1Genomic prescribing system and methodsUNIV CHICAGO·Filed 2014·Application pending·0 cites
- 2145US2023192872A1Tocilizumab for the treatment of viral infectionsUNIV CHICAGO·Filed 2021·Application pending·0 cites
- 2245US2009017452A1Methods and compositions relating to the pharmacogenetics of different gene variantsUNIV CHICAGO·Filed 2005·Application pending·0 cites
- 2343US2003099960A1Compositions and methods for optimizing UGT2B7 substrate dosings and for predicting UGT2B7 substrate toxicityUNIV CHICAGO·Filed 2002·Application pending·0 cites
- 2439US2007275386A1Polymorphisms in the Epidermal Growth Factor Receptor Gene PromoterRATAIN MARK J·Filed 2005·Application pending·0 cites
- 2530US2002016293A1Flavopiridol drug combinations and methods with reduced side effectsFiled 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mark J. Ratain files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →